Serina Therapeutics (SER) Total Current Liabilities (2018 - 2026)

Serina Therapeutics has disclosed Total Current Liabilities across 9 years of filings, most recently posting $3.8 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 5.64% year-over-year to $3.8 million; the TTM figure through Jun 2026 stood at $3.8 million (up 5.64% YoY), while the FY2025 annual figure was $3.6 million, up 50.59% from the prior year.
• Total Current Liabilities came in at $3.8 million for Q2 2026 at Serina Therapeutics, up from $3.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $24.5 million in Q2 2023 to a low of $1.4 million in Q4 2023.
• Average Total Current Liabilities over 5 years is $9.1 million, with a median of $8.8 million recorded in 2022.
• Year-over-year, Total Current Liabilities plunged 85.98% in 2023 and surged 321.79% in 2024.
• Over 5 years, Total Current Liabilities stood at $10.1 million in 2022, then sank by 85.98% to $1.4 million in 2023, then surged by 67.45% to $2.4 million in 2024, then soared by 50.59% to $3.6 million in 2025, then climbed by 5.59% to $3.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $3.8 million in Q2 2026, $3.6 million in Q4 2025, and $8.8 million in Q3 2025.